Literature DB >> 26116720

Anti-PD-1 and Anti-PDL-1 Monoclonal Antibodies Causing Type 1 Diabetes.

Mahnaz Mellati1, Keith D Eaton2, Barbara M Brooks-Worrell3, William A Hagopian4, Renato Martins2, Jerry P Palmer3, Irl B Hirsch5.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26116720     DOI: 10.2337/dc15-0889

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


× No keyword cloud information.
  63 in total

Review 1.  Checkpoint Inhibitors: Applications for Autoimmunity.

Authors:  Anna S Tocheva; Adam Mor
Journal:  Curr Allergy Asthma Rep       Date:  2017-09-27       Impact factor: 4.806

Review 2.  Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies.

Authors:  David J Byun; Jedd D Wolchok; Lynne M Rosenberg; Monica Girotra
Journal:  Nat Rev Endocrinol       Date:  2017-01-20       Impact factor: 43.330

Review 3.  Checkpoint inhibition and melanoma: Considerations in treating the older adult.

Authors:  Claire F Friedman; Jedd D Wolchok
Journal:  J Geriatr Oncol       Date:  2017-05-11       Impact factor: 3.599

4.  Cytocidal macrophages in symbiosis with CD4 and CD8 T cells cause acute diabetes following checkpoint blockade of PD-1 in NOD mice.

Authors:  Hao Hu; Pavel N Zakharov; Orion J Peterson; Emil R Unanue
Journal:  Proc Natl Acad Sci U S A       Date:  2020-11-23       Impact factor: 11.205

5.  Diabetes mellitus secondary to treatment with immune checkpoint inhibitors.

Authors:  V Venetsanaki; A Boutis; A Chrisoulidou; P Papakotoulas
Journal:  Curr Oncol       Date:  2019-02-01       Impact factor: 3.677

Review 6.  Cell Membrane Bioconjugation and Membrane-Derived Nanomaterials for Immunotherapy.

Authors:  Peter Y Li; Zhiyuan Fan; Hao Cheng
Journal:  Bioconjug Chem       Date:  2018-01-11       Impact factor: 4.774

Review 7.  Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer.

Authors:  Iosune Baraibar; Ignacio Melero; Mariano Ponz-Sarvise; Eduardo Castanon
Journal:  Drug Saf       Date:  2019-02       Impact factor: 5.606

8.  Local delivery of checkpoints antibodies.

Authors:  Chao Wang; Yanqi Ye; Zhen Gu
Journal:  Hum Vaccin Immunother       Date:  2016-09-26       Impact factor: 3.452

9.  Fulminant type I diabetes mellitus associated with nivolumab in a patient with relapsed classical Hodgkin lymphoma.

Authors:  Wataru Munakata; Ken Ohashi; Nobuhiko Yamauchi; Kensei Tobinai
Journal:  Int J Hematol       Date:  2016-10-01       Impact factor: 2.490

10.  New onset diabetes after nivolumab treatment.

Authors:  Ricardo Capitao; Carlos Bello; Ricardo Fonseca; Catarina Saraiva
Journal:  BMJ Case Rep       Date:  2018-01-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.